Fusion Antibodies (LON:FAB) Trading Up 17.2% – Time to Buy?

Fusion Antibodies plc (LON:FAB) shot up 17.2% on Tuesday . The stock traded as high as GBX 8.50 ($0.11) and last traded at GBX 8.50 ($0.11). 1,030,108 shares traded hands during mid-day trading, a decline of 39% from the average session volume of 1,693,661 shares. The stock had previously closed at GBX 7.25 ($0.09).

Fusion Antibodies Trading Down 5.6 %

The company has a quick ratio of 2.36, a current ratio of 3.87 and a debt-to-equity ratio of 2.40. The firm has a market capitalization of £7.30 million, a price-to-earnings ratio of -191.25 and a beta of 0.49. The business has a 50-day moving average of GBX 7.90 and a two-hundred day moving average of GBX 5.27.

Fusion Antibodies (LON:FAB) last announced its quarterly earnings data on Tuesday, November 19th. The company reported GBX (0.80) (($0.01)) EPS for the quarter. Fusion Antibodies had a negative return on equity of 152.68% and a negative net margin of 195.95%. Research analysts predict that Fusion Antibodies plc will post -129.9999875 EPS for the current fiscal year.

Fusion Antibodies Company Profile

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation.